BOULDER, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test [NCT03766958]) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures. The data was published in
Click here to view original post
News
Jo Abernathy Joins Catalyst Solutions as Advisory Board Member
Experienced Technology Leader to Drive Technology Solutions and Innovation GREENWOOD VILLAGE, Colo., July 30, 2024 /PRNewswire/ — Catalyst Solutions, a Business Process as a Service (BPaaS) provider for health insurance plans, has announced today that […]
News
Colorado bioscience companies raise over $1 billion for sixth consecutive year
Early-stage companies saw an increase in capital from 2021. Click here to view original post
News
Veterans Day: Taking a Stroll Down Military Memory Lane
The story of the University of Colorado Anschutz Medical Campus, from its origins as an Army hospital to a present-day academic medical campus, includes a proud history of treating and caring for members of the […]
